Crestwood Advisors Group LLC Acquires 2,321 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Crestwood Advisors Group LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,497 shares of the biopharmaceutical company’s stock after acquiring an additional 2,321 shares during the period. Crestwood Advisors Group LLC’s holdings in Gilead Sciences were worth $1,339,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences in the fourth quarter valued at $29,000. Finally, Crews Bank & Trust acquired a new position in Gilead Sciences during the fourth quarter worth $31,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 706,212 shares of company stock valued at $67,324,826 in the last quarter. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on GILD. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Wolfe Research began coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Bank of America reaffirmed a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Stock Performance

GILD opened at $111.03 on Tuesday. The business’s 50-day simple moving average is $95.79 and its 200 day simple moving average is $89.08. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $111.99. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market capitalization of $138.37 billion, a PE ratio of 300.08, a PEG ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.